Covid-19 Pandemic and Vaccine Prospect: Lessons Learnt from HIV/AIDS

Abstract

Recent media reported in India those weeks after first vaccine dose during the trial, a Minister got Covid-19. It may have hogged the headline in regard to India’s Covaxin produced by Bharat Biotech. But, the company soon issued a statement defending itself on this count stating, “Covaxin clinical trials are based on a two-dose schedule, given 28 days apart, and the vaccine has been designed to be efficacious when subjects receive both doses.”